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Objectives The aim of this study was to evaluate the incidence, predictors, and long-term outcomes of patients with in-stent
restenosis (ISR) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for unprotected left
main coronary artery (LMCA) disease.
Background Few data on the clinical course and management of patients experiencing restenosis after DES treatment for
unprotected LMCA disease have appeared.
Methods Between February 2003 and November 2007, 509 consecutive patients with unprotected LMCA disease under-
went DES implantation, with 402 (80.1%) undergoing routine surveillance or clinically driven angiographic
follow-up. A major adverse cardiac event was defined as the composite of death, myocardial infarction (MI), or
target-lesion revascularization.
Results The overall incidence of angiographic ISR in LMCA lesions was 17.6% (71 of 402 patients, 57 with focal-type
and 14 with diffuse-type ISR. Forty patients (56.3%) underwent repeated PCI, 10 (14.1%) underwent bypass sur-
gery, and 21 (29.6%) were treated medically. During long-term follow-up (a median of 31.7 months), there were
no deaths, 1 (2.2%) MI, and 6 (9.5%) repeated target-lesion revascularization cases. The incidence of major ad-
verse cardiac event was 14.4% in the medical group, 13.6% in the repeated PCI group, and 10.0% in the bypass
surgery group (p  0.91). Multivariate analysis showed that the occurrence of DES-ISR did not affect the risk of
death or MI.
Conclusions The incidence of ISR was 17.7% after DES stenting for LMCA. The long-term clinical prognosis of patients with
DES-ISR associated with LMCA stenting might be benign, given that these patients were optimally treated with
the clinical judgment of the treating physician. (J Am Coll Cardiol 2011;57:1349–58) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.041Current practice guidelines recommend coronary artery
bypass grafting (CABG) as the standard revascularization
procedure for patients with unprotected left main coro-
nary artery (LMCA) disease (1–3). More recently, how-
ever, percutaneous coronary intervention (PCI) to treat
an unprotected LMCA has increased in frequency, asso-
ciated with improvements in interventional techniques
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Medical Research and Information, University of Ulsan College of Medicine, Seoul,
Korea. All authors have reported that they have no relationships to disclose.Manuscript received August 9, 2010; revised manuscript received October 4, 2010,
accepted October 4, 2010.and adjunctive drug therapy. The use of PCI to treat
LMCA disease has also been encouraged by the avail-
ability of drug-eluting stents (DES), which significantly
reduce the rates of restenosis and repeat revasculariza-
tion (4 – 6).
Nevertheless, in-stent restenosis (ISR) after DES im-
plantation for unprotected LMCA lesions continues to
occur, with such lesions being more clinically problematic
compared with other coronary lesions. In addition, the
incidence of ISR after DES implantation for unprotected
LMCA disease has not been sufficiently evaluated in large
numbers of patients, and the long-term prognosis of such
patients has not been explored. Therefore, we investigated
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DES Restenosis in Left Main Disease March 22, 2011:1349–58the incidence, predictors, treat-
ment, and long-term clinical
outcomes of patients with reste-
nosis after DES treatment for
unprotected LMCA disease in
real PCI practice.
Methods
Study population and angiographic
follow-up. Between February 2003
and November 2007, 509 patients
with unprotected LMCA disease
(defined as50% stenosis) received
PCI with DES implantation at
the Asan Medical Center, Seoul,
Korea. During this period, DES
was used as the default device for
PCI. All patients treated with
PCI were recommended for rou-
ine angiographic follow-up 6 to 12 months after the
rocedure. However, patients who were at high risk for
rocedural complications of angiography and who had no
ymptoms or signs of ischemia as well as patients who
eclined the recommendation did not undergo routine
ollow-up angiography but routinely checked noninvasive
tress tests (i.e., an exercise treadmill test or a thallium
adionuclide scan) or meticulous clinical follow-up. After
he 1-year period of surveillance angiographic follow-up,
atients underwent annual noninvasive stress tests, explor-
ng the occurrence of inducible ischemia on stress tests (with
r without ischemic chest pain) or the recurrence of isch-
mic symptoms as indicated by a need for repeat angio-
raphic follow-up.
Written informed consent was obtained from all pa-
ients, and the ethics committee of our institution ap-
roved the design of this study and allowed the use of
linical data.
reatment strategy for LMCA-ISR lesions. Stent im-
lantation methods for de novo LMCA lesions have been
escribed (7–9). Angiographic ISR at LMCA lesions,
etected during either surveillance or clinically driven
ngiographic follow-up, was treated by ischemia-driven
epeat revascularization if the stenosis was at least 50% of
he diameter of the target lesion, as documented by a
ositive functional test, ischemic changes on an electrocar-
iogram, or ischemic symptoms. Alternatively, ischemia-
riven repeat revascularization was performed in the absence
f documented ischemia if stenosis was at least 70%,
egardless of the presence or absence of ischemic signs or
ymptoms. Asymptomatic patients with moderate steno-
is (50% to 70%) and no evidence of inducible ischemia
eceived optimal medical treatment with meticulous clin-
cal follow-up. Patients requiring ischemic-driven repeat
evascularization were treated with CABG or repeated
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
ISR  in-stent restenosis
IVUS  intravascular
ultrasound
LMCA  left main coronary
artery
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TLR  target lesion
revascularizationCI at the discretion of individual physicians, after Monsideration of clinical or procedural factors such as a
linical overview, lesion anatomy, the complexity of the
epeat procedure, and patient and physician preferences.
Patients who underwent repeated PCI for LMCA-ISR
esions were treated either with balloon angioplasty alone
r with additional DES stenting; plain or cutting balloon
ngioplasty was usually preferred to treat focal restenotic
esions, with implantation of additional DES preferred
ith diffuse lesions or focal lesions yielding unsatisfactory
mmediate results. Intravascular ultrasound (IVUS)-
uided PCI was routinely used for optimal procedural
esults. After each procedure, patients were maintained
n aspirin indefinitely and clopidogrel (75 mg once daily)
or at least 12 months. Surgical revascularization was
erformed with standard bypass techniques. Whenever
ossible, the internal thoracic artery was preferred for
evascularization of the left anterior descending artery.
nd points and definitions. The primary end point was
he incidence of major adverse cardiac events, defined as
he composite of death, acute myocardial infarction (MI),
r target lesion revascularization (TLR), after initial
reatment for LMCA-ISR.
All events were based on clinical diagnoses as assessed
y individual physicians and were adjudicated by an
ndependent group of clinicians. Death was defined as
eath from any cause. A diagnosis of acute MI was based
n the development of new Q waves in at least 2
ontiguous leads with an elevated creatine kinase myo-
ardial band fraction or an increase in the creatine kinase
yocardial band concentration to 3-fold the normal value
n the absence of pathologic Q waves. Electrocardiogra-
hy and blood sampling for the measurement of creati-
ine kinase and its myocardial band isoenzyme were
outinely performed before stenting, every 8 h for the first
4 h after the procedure and daily thereafter during
ospital stay. A TLR was defined as percutaneous or
urgical revascularization for stenosis either within the
tent or within 5 mm of the stent. Stent thrombosis was
ssessed according to the Academic Research Consor-
ium definitions, with pre-specified key end point being
efinite or probable (10), and by the timing of presenta-
ion; stent thrombosis was classified as acute, subacute,
ate, and very late if it occurred within 24 h, 30 days, 30
ays to 1 year, or 1 year, respectively. All events were
erified carefully and adjudicated by independent clini-
ians. The patterns of ISR were classified as focal
Mehran ISR pattern I) or diffuse (Mehran ISR pattern
I, III, IV) according to geographic position of ISR in
elation to previously implanted stent (11).
ollow-up protocol after LMCA-ISR treatment and
uantitative coronary angiography. After treatment of
MCA-ISR lesions, clinical follow-up was recom-
ended at 1 month, 6 months, 1 year, and annually
hereafter. For validation of complete clinical follow-up
ata, information on vital status was obtained through
ay 31, 2009, from the National Population Registry of
ltrasoun
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March 22, 2011:1349–58 DES Restenosis in Left Main Diseasethe Korea National Statistical Office, with a unique
personal identification number for each patient. To
ensure accurate assessment of clinical end points, addi-
tional information was obtained from visits or telephone
Baseline Clinical, Angiographic, and Procedural Characteristics ofP ti nts Stratified by Angiographic Foll w-UpTable 1 Bas line Clinical, Angiographic, and Procedu al CharacPatients Stratified by Angiographic Follow-Up
Variable
Demographic characteristics
Age (yrs)
Male 36
Cardiac or coexisting conditions
Diabetes mellitus 17
Hypertension 25
Hyperlipidemia 21
Current smoker 15
Previous CVA 3
Previous PCI 1
Renal failure 1
Ejection fraction (%) 61
Ejection fraction 40% 1
Clinical indication
Silent/stable angina 24
Unstable angina 24
Acute MI 2
Lesion characteristics
Location involved
Ostium, midshaft, or both 19
Distal bifurcation 31
Extent of diseased vessel
Left main only 9
Plus single-vessel disease 11
Plus double-vessel disease 15
Plus triple-vessel disease 14
Right coronary artery disease 21
Restenotic lesion 2
Procedural characteristics
Stent type
Sirolimus-eluting stents 46
Paclitaxel-eluting stents 3
Zotarolimus-eluting stents 1
Total number of stents in LMCA lesion
Total length of stents in LMCA lesion
Average stent diameter in LMCA lesion
Total number of stents in a patient (including LMCA and other vessels)
Total length of stents in a patient (including LMCA and other vessels)
Maximal balloon size
Maximal pressure
Use of intra-aortic balloon pump 3
Guidance with IVUS 46
Glycoprotein IIb/IIIa inhibitor treatment 5
Distal bifurcation treatment
Single stenting 15
Complex stenting with 2 stents 15
Data are shown as mean  SD , n (%), or median (interquartile range).
CVA  cerebrovascular accident; IABP  intra-aortic balloon pulsation; IVUS  intravascular u
intervention.contacts with living patients or family members and frommedical records obtained from other hospitals, as neces-
sary. Patients undergoing repeated PCI for treatment of
LMCA-ISR lesions were recommended for repeated
angiographic follow-up 6 to 12 months later to evaluate
ll Population andtics of Overall Population and
rall
509)
With Angiographic
Follow-Up
(n  402)
Without Angiographic
Follow-Up
(n  100) p Value
11.0 60.2 10.8 61.4 11.5 0.35
.17) 289 (71.9) 70 (70.0) 0.71
.0) 133 (33.1) 38 (38.0) 0.35
.3) 203 (50.5) 46 (46.0) 0.42
.7) 164 (40.8) 46 (46.0) 0.35
.5) 118 (29.4) 29 (29.0) 0.95
) 29 (7.2) 4 (4.0) 0.25
.6) 89 (22.1) 25 (25.0) 0.54
) 4 (2.0) 4 (4.0) 0.24
.0–65.0) 61.0 (58.0–65.0) 60.5 (56.2–64.7) 0.22
) 8 (2.0) 5 (5.0) 0.15
0.05
.2) 198 (49.3) 39 (39.0)
.9) 192 (47.8) 54 (54.0)
) 12 (3.0) 7 (7.0)
0.005
.9) 144 (35.8) 51 (51.0)
.1) 258 (64.2) 49 (49.0)
0.49
.3) 68 (16.9) 22 (22.0)
.6) 91 (22.6) 23 (23.0)
.3) 128 (31.8) 25 (25.0)
.9) 115 (28.6) 30 (30.0)
.8) 168 (41.8) 46 (46.0) 0.45
) 23 (5.7) 6 (6.0) 0.92
0.60
.8) 364 (90.5) 92 (92.0)
) 27 (6.7) 7 (7.0)
) 11 (2.7) 1 (1.0)
0.7 1.6 0.7 1.4 0.6 0.02
21.7 35.8 22.5 28.9 17.6 0.005
1.5 3.5 1.4 3.4 1.6 0.63
1.4 2.4 1.5 2.5 1.7 0.95
23.3 56.2 25.4 56.9 22.8 0.72
0.4 3.9 0.4 3.9 0.4 0.43
3.3 17.5 3.2 16.6 3.7 0.02
) 25 (6.2) 12 (12.0) 0.048
.9) 373 (93.0) 88 (88.0) 0.05
.4) 43 (10.7) 10 (10.0) 0.84
0.007
.2) 118 (45.7) 32 (65.3)
.8) 140 (54.3) 17 (34.7)
d; LMCA  left main coronary artery; MI  myocardial infarction; PCI  percutaneous coronaryOverateris
Ove
(n 
60.5
5 (71
3 (34
1 (49
2 (41
0 (29
4 (6.7
5 (22
2 (2.4
.0 (58
6 (3.1
0 (47
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0 (3.9
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9 (7.7
8 (91
3 (10
3 (49
8 (50the incidence of recurrent ISR.
ble 1.
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DES Restenosis in Left Main Disease March 22, 2011:1349–58Coronary angiograms were digitally recorded and as-
sessed offline in a quantitative angiographic core labora-
tory (Asan Medical Center, Seoul, Korea), with an
automated edge-detection system (CASS II, Pie Medi-
cal, Maastricht, the Netherlands) operated by experi-
Clinical, Lesional, and Procedural Characteristics in Patients WithAmong Tho e Receiving Angiographic Follow-UpTable 2 Clini l, Lesi al, and Procedu al Characteristics in PaAmong Those Receiving Angiographic Follow-Up
Variables
Wit
Demographic characteristics
Age (yrs)
Male
Cardiac or coexisting conditions
Diabetes mellitus
Hypertension
Hyperlipidemia
Current smoker
Previous CVA
Previous PCI
Renal failure
Ejection fraction (%)
Ejection fraction 40%
Clinical indication
Silent/stable angina
Unstable angina
Acute MI
Lesion characteristics
Location involved
Ostium, midshaft, or both
Distal bifurcation
Extent of diseased vessel
Left main only
Plus single-vessel disease
Plus double-vessel disease
Plus triple-vessel disease
Right coronary artery disease
Restenotic lesion
Procedural characteristics
Stent type
Sirolimus-eluting stents
Paclitaxel-eluting stents
Zotarolimus-eluting stents
Total number of stents in LMCA lesion
Total length of stents in LMCA lesion
Average stent diameter in LMCA lesion
Total number of stents in a patient (including LMCA and other vessels)
Total length of stents in a patient (including LMCA and other vessels)
Maximal balloon size
Maximal pressure
Use of intra-aortic balloon pump
Guidance with IVUS
Glycoprotein IIb/IIIa inhibitor treatment
Distal bifurcation treatment
Single stenting
Complex stenting with 2 stents
Data are shown as mean  SD, n (%), or median (interquartile range).
CABG  coronary artery bypass grafting; ISR  in-stent restenosis; other abbreviations as in Taenced personnel unaware of the study aims. The Medinaclassification was used to describe the location and
distribution of restenosis (12). By convention, the parent
vessel of the main bifurcation was defined as the left main
into the left anterior descending artery.
Statistical analysis. Continuous variables were compared
ithout ISRs Wi h or Without ISR
ographic Follow-Up
n  402)
ISR
(n  71)
No ISR
(n  331) p Value
0.2 10.8 61.1 9.4 60.0 11.1 0.47
89 (71.9) 44 (62.0) 245 (74.0) 0.04
33 (33.1) 33 (46.5) 100 (30.2) 0.008
03 (50.5) 40 (56.3) 163 (49.2) 0.28
64 (40.8) 33 (46.5) 131 (39.6) 0.28
18 (29.4) 19 (26.8) 99 (29.9) 0.60
29 (7.2) 3 (4.2) 26 (7.9) 0.28
89 (22.1) 17 (23.9) 72 (21.8) 0.69
4 (2.0) 4 (5.6) 4 (1.2) 0.02
(58.0–65.0) 61.0 (58.0–65.0) 60.0 (57.0–64.0) 0.79
8 (2.0) 2 (2.8) 6 (1.8) 0.63
0.86
98 (49.3) 33 (46.5) 165 (49.8)
92 (47.8) 36 (50.7) 156 (47.1)
12 (3.0) 2 (2.8) 10 (3.0)
0.002
44 (35.8) 14 (19.7) 130 (39.3)
58 (64.2) 57 (80.3) 201 (60.7)
0.02
68 (16.9) 5 (7.0) 63 (19.0)
91 (22.6) 14 (19.7) 77 (23.3)
28 (31.8) 32 (45.1) 96 (29.0)
15 (28.6) 20 (28.2) 95 (28.7)
68 (41.8) 27 (38.0) 141 (42.6) 0.48
23 (5.7) 12 (16.9) 11 (3.3) 0.001
0.25
64 (90.5) 62 (87.3) 302 (91.2)
27 (6.7) 5 (7.0) 22 (6.6)
11 (2.7) 4 (5.6) 7 (2.1)
1.6 0.7 2.1 0.8 1.5 0.6 0.001
5.8 22.5 43.2 19.6 34.2 22.8 0.002
3.5 1.4 3.4 0.3 3.5 1.6 0.63
2.5 1.7 2.5 1.6 2.4 1.9 0.37
6.9 22.8 56.8 23.2 56.9 22.4 0.25
3.9 0.4 3.8 0.5 3.9 0.4 0.09
7.5 3.2 16.3 3.1 17.7 3.2 0.002
25 (6.2) 4 (5.6) 21 (6.3) 0.82
73 (93.0) 69 (97.2) 304 (92.1) 0.13
43 (10.7) 8 (11.3) 35 (10.6) 0.86
0.002
18 (45.7) 14 (24.6) 104 (51.7)
40 (54.3) 43 (75.6) 97 (48.3)or Wtient
h Angi
(
6
2
1
2
1
1
61.0
1
1
1
2
1
1
1
3
3
5
1
3
1
1with the t test or the Mann-Whitney U test, and categorical
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March 22, 2011:1349–58 DES Restenosis in Left Main Diseasevariables were compared with the chi-square or Fisher exact
tests, as appropriate.
Cumulative probability and survival curves were con-
structed from Kaplan-Meier estimates and compared with
the log-rank test. Univariate and multivariate Cox regres-
sion analyses were used to identify predictors of ISR.
Baseline, lesion, and procedural variables with a p value
0.1 in univariate analyses were included in multivariable
Cox regression model. The final models were determined by
backward elimination.
To investigate the relationship between the development
of ISR and the subsequent occurrence of hard end points,
such as death, MI, and the composite of death or MI, the
presence or absence of ISR was entered into a time-updated
Cox model (13) adjusted for the covariates, which were
identified by the multivariable Cox model with backward
elimination with the variables listed in Table 2; a p value
0.1 in univariate analysis was the criterion used for
inclusion in the final model. Adjusted covariates included
age, left ventricular ejection fraction, and stent diameter for
death; age, left ventricular ejection fraction, right coronary
artery disease, and IVUS guidance for MI; and age, left
ventricular ejection fraction, stent diameter, right coronary
artery disease, and IVUS guidance for the composite of
death or MI.
All p values were 2-sided, and a p value 0.05 was
considered statistically significant. All statistical analyses were
performed with SPSS (version 12.0 for Windows, SPSS, Inc.,
Chicago, Illinois) and SAS software (version 9.1, SAS Insti-
tute, Inc., Cary, North Carolina).
Figure 1 Overall Study Profile
CABG  coronary artery bypass grafting; DES  drug-eluting stent(s); PCI  percuResults
Incidence, pattern, and clinical presentation of LMCA-ISR.
Between February 2003 and November 2007, a total of
509 consecutive patients with unprotected LMCA dis-
ease underwent PCI with DES implantation. Figure 1
shows the overall study design. Before the scheduled
6-month angiographic follow-up, 7 patients died (5 due
to STEMI presentation with cardiogenic shock, 1 due to
lung cancer, and 1 due to prostate cancer). Of the 502
eligible patients who survived for at least 6 months after
DES implantation, 402 (80.1%) underwent angiographic
follow-up. Table 1 show the clinical, lesional, and pro-
cedural characteristics of the overall population and of
the patients who did and did not undergo angiographic
follow-up. Approximately 82% of the patients, overall,
had additional vessel involvement beyond LMCA le-
sions, and 61% showed distal LMCA involvement.
Sirolimus-eluting stents were predominantly used. Most
baseline characteristics were similar among patients who
did or did not undergo angiographic follow-up, except
that distal bifurcation disease and complex stenting (with
2 stents) for distal bifurcation treatment were more
common in patients who underwent angiographic
follow-up.
During a median follow-up time of 3.4 years (inter-
quartile range: 2.5 to 4.7 years), 28 patients (5.6%) died,
of whom 12 (2.3% of the overall cohort) died of a
cardiovascular disease; 51 (10.0%) including Q-wave 16
(3.2%) and non–Q-wave 35 (7.8%) had an acute MI; and
s coronary intervention.taneou
1354 Lee et al. JACC Vol. 57, No. 12, 2011
DES Restenosis in Left Main Disease March 22, 2011:1349–5850 (10.0%) had a repeat TLR. Compared with patients
with follow-up angiography, those without follow-up
angiography showed higher incidence of all-cause mor-
tality (3.6% vs. 8.0%, log-rank p 0.004) but no difference in
cardiac mortality (2.0% vs. 2.8%, log-rank p  0.12) (Fig. 2).
Angiographic ISR at LMCA lesions was detected in
71 (17.7%; in-stent: 15.2%, in-segment: 17.7%) of the
402 patients who underwent angiographic follow-up. Of
the 71 patients with ISR, 49 (69.0%) were diagnosed
within 1 year, 12 (16.9%) were diagnosed at 1 to 2 years,
8 (11.3%) were diagnosed at 2 to 3 years, and 2 (2.8%)
were diagnosed after 3 or more years. The restenosis
pattern was focal in 57 patients (80.3%) and diffuse in 14
(19.7%). The overall restenosis rate in nonbifurcation
lesion was 9.7% (14 of 144 patients; aorto-ostial 8.3% and
mid-shaft 11.1%), and the rate in bifurcation lesions was
22.1% (57 of 258 patients). The Medina classification
and location of ISR involvement are illustrated in Figure 3.
Eleven patients (15.5%) presented with silent ischemia, 42
(59.2%) presented with stable angina, 17 (23.9%) presented
Figure 2 Long-Term Clinical Outcomes According to Follow-Up
(A) Kaplan-Meier analysis of all-cause mortality-free survival according to follow-up ang
(B) Kaplan-Meier analysis of cardiac mortality-free survival according to follow-with unstable angina, and 1 (1.4%) presented with a
nonfatal MI.
During 3-year follow-up, the cumulative incidence of
definite or probable stent thrombosis was 1.8% (9 patients;
6 definite and 3 probable; 3 acute, 1 subacute, 2 late, and 3
very late) in the overall LMCA-DES patients, but there was
no occurrence in patients with LMCA-ISR.
Predictors of LMCA-ISR. Table 2 shows a comparison of
clinical, lesional, and procedural characteristics between
patients with and without ISR, among those receiving
angiographic follow-up. Patients with ISR were more likely
to be female and had higher rates of diabetes, renal failure,
more severe disease, distal bifurcation disease, and proce-
dural complexities, compared with patients without ISR.
Univariate and multivariate predictors of overall LMCA-
ISR are shown in Table 3. Major determinants of angio-
graphic LMCA-ISR were female sex, existence of a previ-
ous restenotic lesion, total number of stents employed,
existence of distal bifurcation lesions, and use of complex
bifurcation stenting.
graphic Surveillance
hy.
iography.Angio
iograp
up ang
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Among 71 patients with LMCA-ISR, 21 (29.6%) received
medical treatment only, 40 (56.3%) were treated with
repeated PCI (22 by balloon angioplasty and 18 with
additional DES implantation), and 10 (14.1%) underwent
CABG. Table 4 shows the differences in the clinical and
angiographic features of LMCA-ISR among these 3 groups
of patients.
The median follow-up time after initial LMCA-ISR treat-
ment was 31.7 months (interquartile range: 22.4 to 46.6
months). Complete follow-up data for major clinical events
were obtained for all patients. During follow-up, no patient
died, 1 (2.2%) suffered MI, and 6 (11.1%) required repeat
Figure 3 The Medina Classification and Lesion Location of In-S
We use the 3 components of a bifurcation: left main artery (LM) as the main bran
circumflex artery (LCX) as the side branch. It consists in giving a binary value (1, 0) ac
Univariate and Multivariate Predictors of ISRTable 3 Univariate and Multivariate Predict
Variable
Male
Diabetes mellitus
Renal failure
Extent of diseased vessel
Left main only
Plus single-vessel disease
Plus double-vessel disease
Plus triple-vessel disease
Restenotic lesion
Bifurcation involvement
Complex stenting with 2 stents in bifurcation lesion*
Total number of stents
Total length of stents
Maximal balloon pressure
Maximal balloon sizeValues are hazard ratio (95% confidence interval). *Compared with simple cr
ISR  in-stent restenosis.TLR. The overall incidence of major adverse cardiac event-free
survival was 86.6% and did not significantly differ among
patients treated medically, by PCI, or by CABG (85.6% vs.
86.4% vs. 90.0%; p  0.91) (Fig. 4).
To evaluate the clinical impact of LMCA-ISR on serious
clinical outcomes (death or MI), we performed a time-
updated Cox regression analysis. In a multivariate analysis
adjusted for covariates, the development of LMCA-ISR did
not significantly influence the occurrence of death (adjusted
hazard ratio [HR]: 1.37, 95% confidence interval [CI]: 0.38
to 5.00, p 0.63), MI (adjusted HR: 0.88, 95% CI: 0.19 to
4.08, p  0.87), or the composite of death or MI (adjusted
HR: 1.04, 95% CI: 0.35 to 3.15, p  0.94).
Restenosis
ximal, left anterior descending artery (LAD) as the main branch distal, and left
g to whether each of the segments previously defined is compromised or not.
f ISR
ivariate p Value Multivariate p Value
0.38–0.99) 0.045 0.41 (0.24–0.69) 0.007
1.14–2.90) 0.012
1.36–10.25) 0.011
0.022
1.00
0.76–5.86) 0.15
1.49–9.80) 0.005
0.97–6.87) 0.06
2.26–7.84) 0.001 4.59 (2.40–8.77) 0.001
1.34–4.31) 0.003 2.56 (1.27–5.19) 0.009
1.64–5.55) 0.001 2.50 (1.28–4.76) 0.007
1.97–3.43) 0.001 4.76 (2.94–7.67) 0.001
1.00–1.02) 0.003
0.83–0.95) 0.001
0.27–0.98) 0.043tent
ch pro
cordinors o
Un
0.61 (
1.82 (
3.74 (
2.11 (
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0.51 (oss-over stenting of distal bifurcation lesions.
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In a large cohort of consecutive patients undergoing DES
implantation for unprotected LMCA disease, we noted a
cumulative ISR incidence of 17.7%, which might be
higher than rates reported in non-LMCA DES implan-
tation (14 –17). Long-term prognosis after LMCA-ISR
seemed to be benign, given that these patients were
optimally treated with the clinical judgment of the
treating physician.
The rates of angiographic restenosis after LMCA stenting
with DES have been found to vary widely, from 8% to 42%
(4,18–26). We found that the overall incidence of LMCA-
ISR over 3 years was approximately 18%. This disparity in the
incidence of LMCA-ISR among studies might be due to
differences in patient selection, the relative frequency of distal
bifurcation lesions, interventional techniques, and the com-
pleteness and timing of surveillance angiography.
We found that distal bifurcation involvement and a
complex stenting strategy were important predictors of ISR
after DES implantation, findings similar to those of previ-
ous reports on LMCA stenting (27–30). Currently available
evidence suggests that outcomes are less favorable when
distal LMCA lesions are treated with a 2-stent compared
with a single-stent approach. In addition, all measures
required to achieve an optimal final result should be con-
sidered, with IVUS assessment advocated in most patients
for optimization of stent placement.
The choice of treatment strategy (medical treatment,
repeated PCI, or CABG) for LMCA-ISR lesions de-
pends primarily on several clinical and angiographic
Clinical and Angiographic Characteristics ofPatients With ISR, According to Treatment StraTable 4 Clin cal and Angiograph c CharactePatients With ISR, According to Tre
Variable
Medical Ther
(n  21)
Clinical presentation at ISR detection
Silent ischemia 6 (28.6)
Stable angina 13 (61.9)
Unstable angina 2 (9.5)
Acute MI 0 (0)
Location of ISR
LMCA only 1 (4.8)
LAD ostium only 3 (14.3)
LCX ostium only 10 (47.6)
Multiple 7 (33.3)
Type of ISR
Focal pattern 19 (90.5)
Diffuse pattern 2 (9.5)
Quantitative coronary angiography
Reference vessel diameter, mm 4.2 0.6
Lesion length, mm 10.5 3.6
Diameter stenosis, % 60.8 16
Minimal luminal diameter, mm 1.2 0.5
Data are shown as n (%) or mean  SD.
LAD  left anterior descending artery; LCX  left circumflex artery;factors, making optimal patient selection crucial in theappropriate treatment of LMCA-ISR lesions and achieve-
ment of favorable long-term outcomes. We found that
LMCA-ISR treatment strategies were dependent on lesion
characteristics, procedural complexities, the extent of extra-
LMCA disease, patient clinical characteristics (i.e., age,
diabetes, ejection fraction, and other comorbidities), and
patient/physician preference. The 3-year outcomes after
treatment of LMCA-ISR were similar in the medical, PCI,
and CABG groups, indicating that treating physicians
exercised excellent clinical judgment, choosing appropriate
treatment methods on the basis of knowledge of the
coexisting conditions of their patients.
It remains unclear whether routine surveillance angiography
should be mandatory after LMCA stenting. Because patients
with LMCA restenosis are thought to be at high risk for
adverse events, repeat angiography has been suggested, because
detection of even a silent LMCA-ISR might be important.
However, angiography is unable to predict when a patient
might be prone to acute, sudden stent thrombosis, and angiog-
raphy might be associated with a non-negligible risk in patients
who have undergone placement of a left main stent (22,23).
Therefore, recent PCI guidelines do not recommend routine
angiographic follow-up after LMCA stenting. Exploration of
this issue warrants large-scale studies comparing routine and
repeat follow-up angiography with noninvasive, functional
follow-up after LMCA stenting (31).
Study limitations. First, our work was a retrospective,
single-center, observational study. In addition, because we did
not systematically perform angiographic follow-up on all
LMCA patients receiving PCI, we might have underestimated
the “true” incidence of LMCA-ISR. Second, the treatment
s of
nt Strategy
Repeated PCI
(n  40)
CABG
(n  10) p Value
0.036
3 (7.5) 2 (20.0)
25 (62.5) 4 (40.0)
12 (30.0) 3 (30.0)
0 (0) 1 (10.0)
0.87
3 (7.5) 0 (0)
7 (17.5) 3 (30.0)
15 (37.5) 3 (30.0)
15 (37.5) 4 (40.0)
0.14
32 (80.0) 6 (60.0)
8 (20.0) 4 (40.0)
4.1 0.8 3.9 0.9 0.73
7.6 4.4 8.1 4.9 0.025
68.6 13.1 66.4 11.5 0.035
0.8 0.4 0.8 0.5 0.043
bbreviations as in Tables 1 and 2.tegyristic
atme
apy
.9strategy for LMCA-ISR lesions was at the discretion of the
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patients in each group and they were too dissimilar to compare,
so fair comparisons between treatment modalities for treat-
ment of LMCA-ISR lesions are substantially limited due to
selection bias. Third, some of the multivariable models might
be over-fitted on the basis of small numbers of end point
events. Finally, because we evaluated the first generation of
DES, the applicability of our findings to the next generation of
DES—which seem to be associated with somewhat different
efficacy and safety—might be limited.
Conclusions
The incidence of ISR in the 3 years after successful DES
Figure 4 Long-Term Clinical Outcomes of In-Stent Restenosis
(A) Kaplan-Meier analysis of event-free survival after major adverse cardiac events
sis of event-free survival after MACE in patients with left main in-stent restenosis
tion [PCI] vs. coronary artery bypass grafting [CABG]).implantation in consecutive real-world patients with unpro-tected LMCA disease was approximately 18%. Female sex,
initial restenotic lesions, distal bifurcation lesions, and the use
of complex procedures were identified as major predictors of
LMCA-ISR. The clinical consequences of LMCA-ISR after
DES treatment seemed to be benign, with the incidence of
major adverse cardiac event not differing significantly among
treatment modalities, given that these patients were optimally
treated with the clinical judgment of the treating physician.
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